Home›Trial›NCT06419634
🔬NCT06419634Phase 1RECRUITING

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Study Summary

The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions / Drugs
BMS-986497AzacitidineVenetoclax
View on ClinicalTrials.gov ↗
Sponsor
BMY
Bristol-Myers Squibb
Oncology
F35/100
Study Details
Enrollment105 participants
Primary Completion—
Lead SponsorBristol-Myers Squibb
Data Retrieved2026-04-11 04:08:14.745776+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.